SAB Biotherapeutics Inc - Unit (1 Ordinary share & 1/2 Wrt)
BCYPU
Get informed when a big investor buys or sells
+ FollowMarket Cap$343.93M
Close$
Share Statistics
| Market cap | $343.93 Million |
|---|---|
| Enterprise Value | $340.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 0 |
| Outstanding Shares | 79,753,100 |
Return
| Return on Equity | -5.95% |
|---|---|
| Return on Assets | -5.36% |
| Return on Invested Capital | -59.32% |
Valuation & Multiples
| P/E Ratio | -8.44 |
|---|---|
| PEG | -6.9 |
| Price to Sales | - |
| Price to Book Ratio | 4.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.54 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SAB Biotherapeutics Inc
81 employeessab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.